Letters
ATAC trial: reporting interim results is not helpful
BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7402.1329-b (Published 12 June 2003) Cite this as: BMJ 2003;326:1329
This article has a correction. Please see:
- Heather Goodare (hm.goodare@virgin.net), chair,
- Clare Dimmer (clare@solvatec.demon.uk), secretary,
- Kathy Page (kathypage@btinternet.com), treasurer
- Breast UK (Breast-cancer Research Ethics and Advocacy Strategy), Horsham, West Sussex RH13 6DF
- Breast UK Waterlooville, Hants PO7 6LA
- Breast UK Lower Layham, Suffolk IP7 5NA
EDITOR—We should like to raise some concerns about the ATAC (arimidex, tamoxifen alone or in combination) trial, which was reported on in the Lancet after only half the time stipulated in the protocol (2.5 years instead of 5).1 Ravdin has raised important points: “Early reporting rules can powerfully …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.